Open AccessEGFR Amplification in Metastatic Colorectal Cancer
Author(s) -
Giovanni Randon,
Rona Yaeger,
Jaclyn F. Hechtman,
Paolo Manca,
Giovanni Fucà,
Henry Walch,
Jeeyun Lee,
Elena Élez,
Jenny F. Seligmann,
Benedetta Mussolin,
Filippo Pagani,
Marco Maria Germani,
Margherita Ambrosini,
Daniele Rossini,
Margherita Ratti,
Francesc Salvà,
Susan D. Richman,
Henry M. Wood,
Gouri J. Nanjangud,
Annunziata Gloghini,
Massimo Milione,
Alberto Bardelli,
Filippo de Braud,
Federica Morano,
Chiara Cremolini,
Filippo Pietrantonio
Publication year - 2021
Publication title -
journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djab069
Subject(s) - medicine , hazard ratio , colorectal cancer , oncology , cohort , confidence interval , gene duplication , cancer , biology , gene , biochemistry
EGFR amplification occurs in about 1% of metastatic colorectal cancers (mCRCs) but is not routinely tested as a prognostic or predictive biomarker for patients treated with anti-EGFR monoclonal antibodies. Herein, we aimed to characterize the clinical and molecular landscape of EGFR-amplified mCRC.